TRIM37 Gene Mulibrey Nanism Genetic Test | 2,800 AED | DNA Labs UAE

Executive Summary & Core Metrics

Accuracy Guarantee: 99.9% diagnostic sensitivity via ISO-accredited next-generation sequencing.

Premium Logistics: VIP mobile phlebotomy and temperature-controlled cold-chain home collection (daily 8 AM–11 PM).

Clinical Guidance: Telephonic post-test genetic counselling and result interpretation included.

Insurance: Direct billing verification via WhatsApp +971 54 548 8731.

Test Overview & Methodology

The TRIM37 gene Mulibrey nanism genetic test uses next-generation sequencing (NGS) to detect pathogenic variants across the full coding region and flanking intronic boundaries of the TRIM37 gene. This comprehensive approach enables definitive molecular diagnosis of Mulibrey nanism, a rare autosomal recessive syndrome characterized by profound growth delay, constrictive pericarditis, and elevated malignancy risk. Unlike conventional Sanger sequencing, NGS captures single-nucleotide variants, small insertions/deletions, and copy-number alterations in a single assay, with reflex to MLPA if large rearrangements are suspected.

Feature	Our Test (DNA Labs UAE)	Closest Alternative (Sanger Sequencing)
Methodology	NGS – full gene and flanking intronic regions	Sanger Sequencing – exon-wise coverage, may miss deep intronic variants
Analytical Sensitivity	>99.9% for single nucleotide variants and small indels	~98% for coding regions; low sensitivity for mosaic/copy-number variants
Turnaround Time	3–4 weeks	4–6 weeks
Clinical Utility	Comprehensive mutation detection, including large rearrangements (MLPA reflex)	Limited to point mutations; requires additional assays for deletions

Physician Insight & Safety Protocols

"As a consultant medical geneticist, I consider this NGS assay essential for confirming Mulibrey nanism and guiding surveillance for associated complications. However, the molecular result must always be integrated with echocardiographic, endocrine, and growth assessments before any therapeutic adjustment. Genetic data does not replace clinical judgment. I strongly advise never to discontinue prescribed cardiac or hormonal therapies without a comprehensive multidisciplinary review."

— Dr. Lina Osama Zaki Quteineh, Consultant Medical Genetics | DHA: 9294403

Important Medication Advisory

⚠ Medication Warning: Do not stop or modify any prescribed medication without explicit instruction from your managing physician.

This genetic test does not replace medical therapy. Continue all current treatments unless advised otherwise by a qualified healthcare professional.

Safety Exclusion Criteria & Emergency Red Flags

For individuals under 18 years, genetic testing requires explicit parental or guardian consent in accordance with UAE medical liability regulations (Federal Decree-Law No. 4 of 2016).
Testing should not be performed if the patient is unable to provide informed consent or is experiencing acute life-threatening cardiac or hepatic decompensation. Urgent clinical management takes precedence over sample collection.
Seek immediate emergency care if symptoms such as severe dyspnea, hepatomegaly, or signs of constrictive pericarditis develop. Genetic test collection is secondary to acute medical intervention.

Patient FAQ & Clinical Guidance

1. What exactly does this TRIM37 NGS test detect, and why is it essential for Mulibrey nanism?

This test analyzes the full coding sequence of the TRIM37 gene using next-generation sequencing. It identifies pathogenic mutations that cause Mulibrey nanism—a rare syndrome involving severe growth failure, pericardial constriction, and increased cancer risk. The results enable definitive diagnosis, carrier testing for relatives, and tailored surveillance for cardiac and malignant complications.

2. How is the sample collected from home in the UAE, and is it safe and DHA-compliant?

A DHA-licensed phlebotomist visits your home to collect a blood sample (standard EDTA tube or FTA card) following strict cold-chain transport protocols (2–8°C). The collector verifies your identity and informed consent before the procedure. All data handling complies with UAE Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 on health information technology.

3. What do my results mean, and what should I do after receiving them?

A positive result confirms the diagnosis of Mulibrey nanism and directs you toward specialized cardiologic and endocrine follow-up. Variants of uncertain significance require expert genetic counselling for clinical correlation. A negative result does not completely exclude atypical presentations. Every report includes a complementary telephonic clinical guidance session. We recommend prompt consultation with a pediatric cardiologist and endocrinologist to manage potential complications.

UAE Regulatory & Data Privacy Adherence

Data Protection & Compliance Framework

This genetic testing service fully adheres to:

Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) – ensuring secure collection, processing, and storage of your genetic and medical data.
Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields – governing digital health records and telemedicine.
Federal Decree-Law No. 4 of 2016 on Medical Liability – regulating informed consent, patient safety, and professional accountability.

All laboratory operations are conducted under DHA Facility License No. 1143 and comply with ISO 9001:2015 quality management standards.

Clinical & Logistical Metadata

Test Name	TRIM37 Gene Mulibrey Nanism Genetic Test
Price (AED)	2,800 AED
Turnaround Time	3–4 weeks
Sample Type / Matrix	Whole blood (EDTA), Extracted DNA, or FTA Card
Methodology Used	Next Generation Sequencing (NGS) – full gene and flanking intronic regions
ICD-10-CM Code	Q87.8
LOINC Code	8100-9
DHA Facility License & Laboratory Address	DHA Facility License: 1143 \| Laboratory Address: Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE

دعم ثنائي اللغة متاح

التحقق من التغطية التأمينية

Check Insurance Coverage Instantly

Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.

توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.

✅ DHA Certified ✅ ISO 15189 ✅ HIPAA Compliant

💬 التحقق عبر الواتساب Verify via WhatsApp 📞 Call Team

Available in Arabic, English, Hindi & Urdu

🏅

ISMS 27001:2022

📋

ISO Accredited

🔒

HIPAA

All reports reviewed by DHA-Certified physicians